Trial Profile

Efficacy, Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RIX 4414 (Primary) ; DTaP vaccine; Poliovirus vaccine
Indications Diphtheria; Gastroenteritis; Pertussis; Poliomyelitis; Rotavirus infections; Tetanus
Focus Pharmacodynamics; Registrational; Therapeutic Use
Sponsors GlaxoSmithKline

Most Recent Events

15 Feb 2020 Results of pooled analysis from nine studies including this study published in the Journal of Infectious Diseases.
26 Jul 2012 Actual patient number changed from 3340 to 3345 added as reported by ClinicalTrials.gov.
25 May 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com